Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment.
about
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibitionCovalent histone modifications--miswritten, misinterpreted and mis-erased in human cancersHypoxia-inducible factors and the response to hypoxic stressCompensatory angiogenesis and tumor refractorinessPHD2: from hypoxia regulation to disease progressionProlyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancerProlyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancerAntimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healingThe role of PHD2 mutations in the pathogenesis of erythrocytosis.Prolyl-4-hydroxylase domain protein 2 controls NF-κB/p65 transactivation and enhances the catabolic effects of inflammatory cytokines on cells of the nucleus pulposus.HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cellsEndothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenograftsComparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics.The function of hypoxia-inducible factor (HIF) is independent of the endoplasmic reticulum protein OS-9Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survivalRoles of individual prolyl-4-hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice.Suppression of glioma progression by Egln3The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapyLoss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR.Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer.Genetic targeting of sprouting angiogenesis using Apln-CreER.The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.HIF-1α restricts NF-κB-dependent gene expression to control innate immunity signalsEpidermal or dermal specific knockout of PHD-2 enhances wound healing and minimizes ischemic injury.Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumor-derived angiogenesis.Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications.HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemiaSynthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling.Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing.Cnidium officinale extract and butylidenephthalide inhibits retinal neovascularization in vitro and in vivoTargeting chemokine pathways in esophageal adenocarcinoma.Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis.Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasisDisrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responsesInhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis.Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions
P2860
Q21261281-49E95999-17A4-49D0-A92B-0C667ADA3839Q24605342-BBFD07AB-43CA-4095-8025-AD6D2E774B77Q24629323-6E54FA24-631D-478E-85DF-3CEB7459C11CQ26851916-5C08AED0-6174-4FAC-9222-6BA1B475110FQ28069316-C80BAB92-2942-48D3-9050-5E652F13D494Q28244168-73D164AA-6E5B-4C4B-80D4-7DC3A994355BQ28257189-B95E232F-BC6E-45BA-AAF5-4D70915AA5E8Q28478087-FE1BAC64-3594-4188-B40A-A430110335B3Q28598099-403E1644-A1F4-4A3B-BDC8-D8D5D884E72EQ30360231-7CEA70C7-B1DA-4206-8BEC-090D0646DBC6Q30565644-627F76FB-4250-4AF3-A03B-AA7BEA1DAEB9Q33614677-0F8F3C6B-CA7F-4821-9398-259D8C9ECF94Q33618949-4FE22CFF-48D9-4518-A173-623B44AD05B9Q33811587-D933733E-72DC-4983-B427-CCA3CDE6B8ECQ33895152-3D507C13-8BFA-4C6C-B74B-CA42101E8404Q34009639-962FADE0-CAFC-4266-A9A1-246EA0948C11Q34276898-7111F6C0-09BF-4527-ACF7-E63BB2A52254Q34384193-E03FB7A3-8C14-4ADB-95E1-9F1DC42D7825Q34596902-387EBC89-96A5-40B5-BCC9-855EB8C7D7A0Q34677727-7EC000B3-202A-4724-85BD-44012D3B2D61Q34990566-3F28E8AA-9282-4EE2-A811-66FDAF8BDA1DQ35023052-A9AF89AC-875A-4FAA-BD96-49523DF7B9A8Q35029578-DDDCB1E5-2470-4CB6-8C11-0DE4A1259CD9Q35041362-0BC39541-662D-4FCA-B740-A3F9AADE2CC5Q35138460-EE057A65-012D-4FC7-9F15-C4EA0197F6DCQ35223479-F5B2A532-6C5E-4D6F-B79E-F06EC9D9DE62Q35586330-32BDD81B-FE37-4CF7-8495-F6636B36D0E1Q35602354-72DD3566-66D8-411A-982B-BA51F5577F48Q35642994-BC6CF258-49FD-469B-AC96-8AFFDBF8190FQ35823747-73F17945-411C-4D36-8698-7A62D5E3CA14Q35952104-AA01C4B8-1811-4A2E-9DD9-B6D13A56A86CQ36082268-DFC4E558-0218-416A-911D-AD9AAC429050Q36187424-4CF7B51B-CA12-475B-AF59-E4D97167E1DAQ36315338-AC732C61-B682-4127-A460-29EC8B4EA750Q36319395-A68ECA54-7E7B-478A-996A-BA473483DD1BQ36327483-227CE404-42CF-4FC7-B787-06732FF70053Q36340825-296A9200-90DD-4373-B708-95E9B452F6ABQ36436005-0EB9CC2F-9DF7-4335-8A3C-A45E5AF6FCA6Q36476333-02C10C97-FEE5-4454-A0BB-D8B4AB772E1BQ36544675-763007E4-B61D-4412-B282-DA3551175104
P2860
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@ast
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@en
type
label
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@ast
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@en
prefLabel
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@ast
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@en
P2093
P2860
P1433
P1476
Tumor vasculature is regulated ...... rrow-derived cell recruitment.
@en
P2093
Amato J Giaccia
Denise A Chan
Howard Y Chang
Jen-Tsan Chi
Patrick D Sutphin
Tiara L A Kawahara
P2860
P304
P356
10.1016/J.CCR.2009.04.010
P577
2009-06-01T00:00:00Z